Clinical Outcomes of CLL and MCL Patients Treated With Ibrutinib: An Observational Retrospective Medical Chart Review From India

Trial Profile

Clinical Outcomes of CLL and MCL Patients Treated With Ibrutinib: An Observational Retrospective Medical Chart Review From India

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 05 Apr 2018 Planned End Date changed from 16 Jul 2018 to 31 Jul 2018.
    • 05 Apr 2018 Planned initiation date changed from 6 Apr 2018 to 16 Apr 2018.
    • 02 Apr 2018 Planned initiation date changed from 30 Mar 2018 to 6 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top